RxDoctor Payments Data

Njambi Mathenge, MD

Cardiovascular Disease · Lebanon, NHNPI 1285053488

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,321 of the $1,660 with a category attached, or 79.6%. 7 manufacturers reported payments, led by Alcon at 31.3% of the total. Reporting peaked in 2024 at $1,121 and has fallen 98.3% since, to $19 in 2025.

$1,660in general payments, 2019–2025

Across 25 payments — averaging $66.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$520
  • Teleflex LLC$291
  • Spectrawave, Inc$269
  • Medtronic$229
  • Reflow Medical Inc$199
  • Abiomed$136
  • plus $16 from 1 others

What the payments were for

  • Consulting fees$25015%
  • Travel & lodging$895%
  • Food & beverage$1,32180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon12$520
Teleflex LLC2$291
Spectrawave, Inc2$269
Medtronic5$229
Reflow Medical Inc2$199
Abiomed1$136
Pfizer1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,660 in reported general payments places this provider in the 60th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$14,873
Medicare patients
43
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate28$276
Isosorbide Mononitrate ErIsosorbide Mononitrate16$185
Amlodipine Besylate12$104

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →